UBX News and Press, Unity Biotechnology Inc. From 10/24/22

Summary A small cap biotech targeting diseases of ageing, with a lead compound focusing on ophthalmology that recently reported positive trial results. Not overly reliant on debt and has reported some revenues with relatively stable overall financials. Recently underwent a 10-...

Unity Biotechnology ( NASDAQ: UBX ) announced on Wednesday a 1-for-10 reverse stock split of its common stock, sending its shares down 7.6% in premarket trading. The reverse stock split will become effective at 5:00 PM on Wednesday. The company said it was goin...

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that its Board of Directo...

- Presentations from UNITY’s leadership team and fireside chat with retina expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 from 8:00 a.m. to 9:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UB...

-Webinar to feature presentation from retinal expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 at 5:00 a.m. PT/8:00 a.m. ET- SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing ...

Enrollment of 51 patients exceeds target by ~10% due to high interest in the study 16-week data anticipated in Q1 2023 and 24-week data anticipated in Q2 2023 SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those affecting growth comp...

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will participate in the following i...

Unity Biotechnology ( NASDAQ: UBX ) has halved a stock sales agreement to $25M from $50M , according to a Friday SEC filing. The sales agreement is through Cowen. Unity noted that it already sold $8.9M worth of shares under the agreement. On Thursday, the compa...

UNITY Biotechnology ( NASDAQ: UBX ) is down 4.95% after-hours after the firm has priced an upsized underwritten public offering of 64,285,714 shares of its common stock and accompanying warrants to purchase up to 64,285,714 shares of common stock at a combined public offer...